Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.

Authors :: Theken KN
Lee CR
Gong L
Caudle KE
Formea CM
Gaedigk A
Klein TE
Agúndez JAG
Grosser T
Source :: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2020 Aug; Vol. 108 (2), pp. 191-200. Date of Electronic Publication: 2020 Apr 28.
Publication Year :: 2020
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for NSAIDs based on CYP2C9 genotype (updates at www.cpicpgx.org).<br /> (© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.)

Subjects :: Anti-Inflammatory Agents, Non-Steroidal adverse effects
Clinical Decision-Making
Consensus
Cytochrome P-450 CYP2C9 metabolism
Drug Interactions
Drug-Related Side Effects and Adverse Reactions enzymology
Genotype
Humans
Phenotype
Predictive Value of Tests
Risk Assessment
Risk Factors
Anti-Inflammatory Agents, Non-Steroidal pharmacokinetics
Cytochrome P-450 CYP2C9 genetics
Drug-Related Side Effects and Adverse Reactions genetics
Pharmacogenetics standards
Pharmacogenomic Testing standards
Pharmacogenomic Variants

Full Text Access

Tools